A method for producing a phenylacetamide compound represented by formula (1):
wherein Q represents a hydrogen atom or a halogen atom, R
2
represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, R
4
represents an alkyl group having 1 to 4 carbon atoms, Ar represents an unsubstituted or substituted phenyl group, R
5
represents R
4
when R
2
is a hydrogen atom, and R
5
represents a hydrogen atom when R
2
is an alkyl group having 1 to 4 carbon atoms; including reacting a phenylacetamide compound represented by formula (2):
wherein Q, R
2
and Ar have the same meanings as defined above; with a dialkyl sulfate represented by formula (3):
wherein R
4
has the same meaning as defined above;
in the presence of a base.
[EN] AMIDOIMIDAZOPYRIDAZINES AS MKNK-1 KINASE INHIBITORS<br/>[FR] AMIDOIMIDAZOPYRIDAZINES À TITRE D'INHIBITEURS DE KINASES MKNK-1
申请人:BAYER PHARMA AG
公开号:WO2014118135A1
公开(公告)日:2014-08-07
The present invention relates to amido-substituted imidazopyridazine compounds of general formula (I) : in which A, R1, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper- proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
[EN] INHIBITORS OF THE WNT SIGNALLING PATHWAYS<br/>[FR] INHIBITEURS DES VOIES DE SIGNALISATION WNT
申请人:BAYER PHARMA AG
公开号:WO2015140196A1
公开(公告)日:2015-09-24
The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper- proliferative disorder, as a sole agent or in combination with other active ingredients.
Ionic liquid containing phosphonium ion and method for producing the same
申请人:Sueto Kumiko
公开号:US20090023954A1
公开(公告)日:2009-01-22
An ionic liquid of the present invention is “an ionic liquid comprising an organic substance represented by the following general formula (1) as a cation component” and “an ionic liquid comprising a cation component and an anion component, and the cation component is one or plural kinds selected from the group consisting of cation components represented by the following formula (1)”.
Problem to be Solved
It is intended to provide an industrially preferable fluoroalkylating agent and use thereof.
Solution
The present invention provides a fluoroalkylating agent represented by the general formula (1) wherein R
1
is a C1 to C8 fluoroalkyl group; R
2
and R
3
are each independently a C1 to C12 alkyl group or the like; Y
1
to Y
4
are each independently a hydrogen atom, a halogen atom, or the like; and X
−
is a monovalent anion.
A compound of the general formula (3): R
4
—S—R
1
having an introduced C1 to C8 fluoroalkyl group is easily obtained by reacting a compound of the general formula (2): R
4
—S—Z wherein R
4
is a hydrocarbon group or the like; and Z is a leaving group, with the compound of the general formula (1).